フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
* Total revenues increased by 50% to 19.7 million euro (2004: 13.1 million euro) * Operating loss (EBIT) reduced by 22% to -11.5 million euro...
MARTINSRIED, Germany and SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- The Executive Board of the German-American biotech company MediGene AG...
- MediGene Receives Milestone Payment for Launch in France - MediGene's First Drug* Now Available in 11 European Countries MARTINSRIED, Germany...
MARTINSRIED/MUNICH, Germany and SAN DIEGO, Feb. 14 /PRNewswire-FirstCall/ -- The German-American biotech company MediGene AG (German Stock...
* Bradley acquires US commercialization rights for genital warts and other dermatological diseases. MediGene retains full rest of world...
* A non-exclusive license under existing tumor-vaccine patents MARTINSRIED, Germany and MUNICH, Germany, and SAN DIEGO, Dec. 19...
MARTINSRIED and MUNICH, Germany and SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- The German-American biotech company MediGene AG (Frankfurt...
* Total revenues of 8.6 million euro (9M-2004: 11.5 million euro) MARTINSRIED/MUNICH, Germany and SAN DIEGO, Nov. 2 /PRNewswire-FirstCall/...
MARTINSRIED, Germany and SAN DIEGO, Aug. 24 /PRNewswire-FirstCall/ -- Today the German-American biotech company MediGene AG (Frankfurt, Prime...
* Total revenues of 4.9 million euro (H1-2004: 8.8 million euro) * Net loss -6.3 million euro (H1-2004: -4.2 million euro) * Operational cash flow...
MediGene to Present at Fourth Annual Needham Biotechnology Conference in New York City MARTINSRIED/MUNICH, Germany and SAN DIEGO, May 23...
Again MediGene AG Significantly Improves Quarterly Result * Net loss -0.9 million EUR (Q1-2004: -1.5 million EUR) * Total revenues 3.8 million EUR...
MediGene Announces Webcast of Analyst Conference and Conference Call of 2004 Year End Results Analyst Conference to be Held on March 23 in...
MediGene to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference MARTINSRIED, Germany and SAN DIEGO, Oct. 22...
MediGene Initiates Clinical Phase I/II Trial of Cancer-Killing Virus NV1020 for the Treatment of Liver Metastases MARTINSRIED, Germany and SAN...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約